Datamonitor Healthcare has identified the following key highlights from the 50th American Society of Clinical Oncology (ASCO) Annual Meeting, which was held between 30 May and 3 June 2014:
Results from early-phase clinical trials of AstraZeneca’s AZD9291
Imbruvica's (Ibrutinib; Pharmacyclics/Janssen Biotech) Phase III RESONATE results
Results from the Phase II ROMULUS trial
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: